PHRRF (PharmaTher Holdings) LT-Debt-to-Total-Asset: 0.00 (As of Feb. 2026)


What is PharmaTher Holdings LT-Debt-to-Total-Asset?

PharmaTher Holdings PHRRF +6.29% LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PharmaTher Holdings's long-term debt to total assests ratio for the quarter that ended in Feb. 2026 was 0.00.

PharmaTher Holdings's long-term debt to total assets ratio stayed the same from Feb. 2025 (0.00) to Feb. 2026 (0.00).

PharmaTher Holdings  (OTCPK:PHRRF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PharmaTher Holdings LT-Debt-to-Total-Asset Related Terms

PharmaTher Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for PharmaTher Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaTher Holdings LT-Debt-to-Total-Asset Chart

PharmaTher Holdings Annual Data
Trend May21 May22 May23 May24 May25
LT-Debt-to-Total-Asset
0.00 0.00 0.00 0.00 0.00

PharmaTher Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PharmaTher Holdings LT-Debt-to-Total-Asset Calculation

PharmaTher Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in May. 2025 is calculated as

LT Debt to Total Assets (A: May. 2025 )=Long-Term Debt & Capital Lease Obligation (A: May. 2025 )/Total Assets (A: May. 2025 )
=0/0.966
=

PharmaTher Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2026 is calculated as

LT Debt to Total Assets (Q: Feb. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2026 )/Total Assets (Q: Feb. 2026 )
=0/0.779
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
PharmaTher Holdings (PHRRF) has a LT-Debt-to-Total-Asset of 0.00 as of Feb. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PharmaTher Holdings and its competitors.
Is PharmaTher Holdings' LT-Debt-to-Total-Asset too high?
PharmaTher Holdings' current LT-Debt-to-Total-Asset is 0.00.
How does PharmaTher Holdings' LT-Debt-to-Total-Asset compare to VRTX and REGN?
PharmaTher Holdings' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PharmaTher Holdings and its competitors. PharmaTher Holdings's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaTher Holdings stock overvalued right now?
PharmaTher Holdings (PHRRF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For PharmaTher Holdings (PHRRF), the current LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaTher Holdings Business Description

Other Exchanges NCC0:GermanyPHRM:Canada
Address 82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch and others.